Stock Analysis

President Elizabeth Barrett Just Bought 4.6% More Shares In UroGen Pharma Ltd. (NASDAQ:URGN)

  •  Updated
NasdaqGM:URGN
Source: Shutterstock

Potential UroGen Pharma Ltd. (NASDAQ:URGN) shareholders may wish to note that the President, Elizabeth Barrett, recently bought US$185k worth of stock, paying US$18.50 for each share. Although the purchase only increased their holding by 4.6%, it is still a solid purchase in our view.

View our latest analysis for UroGen Pharma

The Last 12 Months Of Insider Transactions At UroGen Pharma

Notably, that recent purchase by Elizabeth Barrett is the biggest insider purchase of UroGen Pharma shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$18.44). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Elizabeth Barrett was the only individual insider to buy during the last year.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
NasdaqGM:URGN Insider Trading Volume December 16th 2020

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of UroGen Pharma

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 8.6% of UroGen Pharma shares, worth about US$35m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The UroGen Pharma Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in UroGen Pharma shares, given these transactions (along with notable insider ownership of the company). So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 3 warning signs for UroGen Pharma you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

When trading UroGen Pharma or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


What are the risks and opportunities for UroGen Pharma?

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

View Full Analysis

Rewards

  • Trading at 95.1% below our estimate of its fair value

  • Earnings are forecast to grow 56.11% per year

Risks

  • Negative shareholders equity

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report